|
 Both tested doses of the drug, epidiolex, were found to have induced
a statistically significant improvement in reducing seizures in
patients with Lennox-Gastaut syndrome (LGS), GW said on Monday.
LGS is a disease that is characterized by seizures, impaired
intellectual functioning, developmental delays and behavioral
disturbances.
The drug had already succeeded in another late-stage study in LGS
and GW has also announced positive results from a late-stage study
on patients with Dravet syndrome, another severe form of epilepsy.
GW said it expects to submit a marketing application for the drug to
the U.S. Food & Drug Administration in the first half of 2017. If
approved, it could become the first drug in the country to be made
from organic cannabis.
[to top of second column] |
The company's shares rose as much as 10.2 percent to hit a record
high of 770 pence on the London Stock Exchange.
(Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
